StockTake: Orthocell to enter the US market

Orthocell has appointed the first four US distributors for its flagship nerve repair product Remplir.

Regenerative medicine developer Orthocell (ASX:OCC) has appointed the first four US distributors for its flagship nerve repair product Remplir.

The appointments follow FDA clearance for Remplir which landed earlier this month, and Orthocell are expecting first sales in the US very soon.

Today, the US' nerve repair market is valued at US$1.6 billion. Orthocell will tap this market through distributors in Michigan, Virginia, Colorado and Indiana.

Orthocell aims to appoint up to 10 US distributors by the end of June this year.

Watch the video to hear more.

This video was developed in collaboration with Orthocell, a Stockhead advertiser at the time of publishing.

This video does not constitute financial product advice. You should consider obtaining independent advice before making any financial decisions.

Originally published as StockTake: Orthocell to enter the US market